- Home
- NUVL vs CACC Comparison
NUVL vs CACC Comparison
Compare NUVL & CACC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- CACC
- Stock Information
- Founded
- NUVL 2017
- CACC 1972
- Country
- NUVL United States
- CACC United States
- Employees
- NUVL N/A
- CACC N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- CACC Finance: Consumer Services
- Sector
- NUVL Health Care
- CACC Finance
- Exchange
- NUVL Nasdaq
- CACC Nasdaq
- Market Cap
- NUVL 6.7B
- CACC 6.0B
- IPO Year
- NUVL 2021
- CACC 1992
- Fundamental
- Price
- NUVL $87.30
- CACC $494.40
- Analyst Decision
- NUVL Strong Buy
- CACC Strong Sell
- Analyst Count
- NUVL 10
- CACC 1
- Target Price
- NUVL $112.60
- CACC $380.00
- AVG Volume (30 Days)
- NUVL 350.8K
- CACC 71.7K
- Earning Date
- NUVL 11-12-2024
- CACC 01-29-2025
- Dividend Yield
- NUVL N/A
- CACC N/A
- EPS Growth
- NUVL N/A
- CACC N/A
- EPS
- NUVL N/A
- CACC 15.07
- Revenue
- NUVL N/A
- CACC $846,100,000.00
- Revenue This Year
- NUVL N/A
- CACC N/A
- Revenue Next Year
- NUVL N/A
- CACC $9.88
- P/E Ratio
- NUVL N/A
- CACC $32.57
- Revenue Growth
- NUVL N/A
- CACC N/A
- 52 Week Low
- NUVL $61.80
- CACC $409.22
- 52 Week High
- NUVL $113.51
- CACC $616.66
- Technical
- Relative Strength Index (RSI)
- NUVL 36.14
- CACC 59.14
- Support Level
- NUVL $84.64
- CACC $483.23
- Resistance Level
- NUVL $89.31
- CACC $497.38
- Average True Range (ATR)
- NUVL 2.82
- CACC 11.30
- MACD
- NUVL -0.72
- CACC 0.06
- Stochastic Oscillator
- NUVL 20.93
- CACC 71.70
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About CACC Credit Acceptance Corporation
Credit Acceptance Corp is a consumer finance company that specializes in automobile loans. These loans are offered through a U.S. nationwide network of automobile dealers that benefit from sales of vehicles to consumers who could otherwise not obtain financing. The company also benefits from repeat and referral sales, and from sales to customers responding to advertisements for financing, but qualify for traditional financing. The company derives its revenue from finance charges, premiums earned on the reinsurance of vehicle service contracts, and other fees. Of these, financing charges, including servicing fees, are by far a source of revenue.